Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, eczema, and impaired skin barrier. In recent years we have seen significant advances in the treatment of AD, with the introduction of new topical and systemic therapies. In addition to basic therapy and classic topical steroids and calcineurin inhibitors other topical substances and for severe forms systemic biologics and Janus kinase inhibitors are now available. Therapy selection is individualized, level-based considering disease severity, and regarding comorbidities and patient preferences. This article provides an up-to-date overview of evidence-based therapeutic options, discusses their efficacy and safety, and offers an outlook on future developments.
Lang et al. (Mon,) studied this question.